Skip to main content
ProMIS Neurosciences Inc. logo

ProMIS Neurosciences Inc. — Investor Relations & Filings

Ticker · PMN ISIN · CA74346M1095 LEI · 5299007HZF79F9IAXI53 US Professional, scientific and technical activities
Open in API
Filings indexed 333 across all filing types
Latest filing 2025-09-24 Director's Dealing
Country CA Canada
Listing US PMN

About ProMIS Neurosciences Inc.

https://www.promisneurosciences.com/

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on the discovery and development of selective antibody therapeutics for neurodegenerative and other misfolded protein diseases. The company leverages a proprietary technology platform to design and generate antibodies that selectively target toxic oligomers, which are key drivers of diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and multiple system atrophy (MSA). Its lead product candidate, PMN310, is in clinical development for Alzheimer's disease. The company's approach aims to provide effective treatments while potentially reducing side effects associated with less specific therapies.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2025-09-24 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is a preliminary proxy statement for a Special Meeting of shareholders of ProMIS Neurosciences Inc. The document includes detailed information about the meeting agenda, voting procedures, and shareholder instructions. It is not an announcement of voting results, nor is it a report of financial results or management discussion. The document is a proxy solicitation material intended to provide shareholders with information to make informed voting decisions at the meeting. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length is substantial (15,000 characters), indicating it is the full proxy statement, not just a brief announcement or notice.
2025-09-23 English
Regulatory Filings 2025
Regulatory Filings
2025-09-11 English
Capital/Financing Update 2025
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It is a formal communication related to the registration process of securities, specifically a request under Rule 461 of the Securities Act of 1933. The content does not contain financial data, report content, or detailed disclosures but is rather an administrative request related to a capital markets filing. This fits the category of Capital/Financing Update (CAP), which includes updates on company fundraising and registration statements for securities offerings.
2025-09-08 English
OWNERSHIP DOCUMENT
Director's Dealing
2025-09-08 English
Regulatory Filings 2025
Regulatory Filings
2025-09-08 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.